- have received any sars-cov-2 vaccine outside of the bnt162-01 or bnt162-04 trials. - have a known allergy, hypersensitivity, or intolerance to the planned imp including any excipients of the imp. - have a current febrile illness (body temperature ≥38.0°c) or other acute illness within 48 hours prior to day 1/imp injection in this trial. participants who screen-fail on this criterion may be rescreened. - have received a live or live attenuated vaccine within 30 days prior to day 1/imp injection, or any other vaccination within 14 days prior to day 1/imp injection. participants who screen-fail on this criterion may be rescreened. - have an ongoing ae assessed as related to any bnt162-01 or bnt162-04 trial vaccine.

- have received any sars-cov-2 vaccine outside of the bnt162-01 or bnt162-04 trials. - have a known allergy, hypersensitivity, or intolerance to the planned imp including any excipients of the imp. - have a current febrile illness (body temperature ≥38.0°c) or other acute illness within 48 hours prior to day 1/imp injection in this trial. participants who screen-fail on this criterion may be rescreened. - have received a live or live attenuated vaccine within 30 days prior to day 1/imp injection, or any other vaccination within 14 days prior to day 1/imp injection. participants who screen-fail on this criterion may be rescreened. - have an ongoing ae assessed as related to any bnt162-01 or bnt162-04 trial vaccine.

- have received any sars-cov-2 vaccine outside of the bnt162-01 or bnt162-04 trials. - have a known allergy, hypersensitivity, or intolerance to the planned imp including any excipients of the imp. - have a current febrile illness (body temperature ≥38.0°c) or other acute illness within 48 hours prior to day 1/imp injection in this trial. - have received a live or live attenuated vaccine within 30 days prior to day 1/imp injection, or any other vaccination within 14 days prior to day 1/imp injection. - have an ongoing ae assessed as related to any bnt162-01 or bnt162-04 trial vaccine.

- have received any sars-cov-2 vaccine outside of the bnt162-01 or bnt162-04 trials. - have a known allergy, hypersensitivity, or intolerance to the planned imp including any excipients of the imp. - have a current febrile illness (body temperature ≥38.0°c) or other acute illness within 48 hours prior to day 1/imp injection in this trial. - have received a live or live attenuated vaccine within 30 days prior to day 1/imp injection, or any other vaccination within 14 days prior to day 1/imp injection. - have an ongoing ae assessed as related to any bnt162-01 or bnt162-04 trial vaccine.